IP Verse

Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione - EP3042659

The patent EP3042659 was granted to Celgene on Dec 19, 2018. The application was originally filed on Sep 3, 2004 under application number EP15199521A. The patent is currently recorded with a legal status of "Revoked".

EP3042659

CELGENE
Application Number
EP15199521A
Filing Date
Sep 3, 2004
Status
Revoked
Jul 3, 2020
Publication Date
Dec 19, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BACHELINAug 7, 2019HOFFMANN EITLE -
GENERICS UKAug 7, 2019ELKINGTON AND FIFE -
HAMM & WITTKOPPAug 7, 2019HAMM & WITTKOPP -
HOFFMANN EITLEJul 25, 2019HOFFMANN EITLEADMISSIBLE
PRUSSJul 25, 2019HOFFMANN EITLEADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20030411649
DESCRIPTIONUS20030411656
DESCRIPTIONUS20030438213
DESCRIPTIONUS20030693794
DESCRIPTIONUS20030699154
DESCRIPTIONUS5635517
DESCRIPTIONUS6114335
DESCRIPTIONUS6235756
DESCRIPTIONUS6281230
OPPOSITIONWO9803502
OTHEREP1667682
OTHERWO9803502
SEARCHUS2002045643

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- KNAPMAN, K., MODERN DRUG DISCOVERIES, (2000), vol. 53
DESCRIPTION- P. DIMARTINO ET AL., J. THERMAL ANAL., (1997), vol. 48, pages 447 - 458
OPPOSITION- "2.20 Recrystallization Techniques", Brian S. Furniss et al.,, VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, Pearson Education Limited, (19890000), pages 135 - 139, XP055627461
OPPOSITION- Brian S Furniss; Et Al, Vogel's Textbook of Practical Organic Chemistry, (19890000), pages 135 - 139, XP055627461
OPPOSITION- "Common Physical Techniques in Purification", Armarego Wilfred L F; Chai Christina L L, PURIFICATION OF LABORATORY CHEMICALS, Fifth Edition, Elsevier Science (USA), (20030000), pages 14 - 16, XP055627845
OPPOSITION- G. MUFTI et al., "Myelodysplastic Syndrome", Hematology, (20030000), pages 176 - 199, XP055627855
OPPOSITION- J.W. MULLIN, CRYSTALLIZATION, Fourth Edition, Reed Educational and Professional Publishing Ltd., (20010000), pages 280-284, 300 - 302, XP055627847
OPPOSITION- "Molecular structure properties and states of matter", Alfonso Gennaro, Remington`s Pharmaceutical Sciences, MAck Publishing Company, (1985), page 185, XP055443314
OPPOSITION- MINO R. CAIRA, "Crystalline polymorphism of organic compounds", Topics in Current Chemistry, (19980000), vol. 198, XP008166276
OPPOSITION- BYRN et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, doi:doi:10.1023/A:1016241927429, pages 945 - 954, XP055399407
OPPOSITION- BYRN S. et al., "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP055399407
OPPOSITION- STEPHEN BYM et al., "Pharmaceutical solids: a strategic approach to regulatory considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, XP055399407
OPPOSITION- STEPHEN BYRN et al., "Pharmaceutical solids: a strategic approach to regulatory considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, XP055399407
OPPOSITION- RICHARDSON et al., "Thalidomide: Emerging Role in Cancer Medicine", Annual Review of Medicine, (20020200), vol. 53, pages 629 - 657, XP055177555
OPPOSITION- P.G. RICHARDSSON et al., "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma", Blood, (20020000), vol. 100, pages 3063 - 3067, XP001188161
OTHER- Jerry March, Advanced Organic Chemistry - Reactions, Mechanisms, and Structure. 4th ed., John Wiley & Sons, (19920000), pages 1208,1216 - 1217, XP055500709
OTHER- RICHARDSON P. et al, "Thalidomide in multiple myeloma", Biomed. Pharmacother., (20020500), vol. 56, no. 3, pages 115 - 128, XP002507888
OTHER- Muller G. W. et al, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production", Bioorganic & Medicinal Chemistry Letters, (19990607), vol. 9, no. 11, pages 1625 - 1630, XP004169632
OTHER- Patrick A. J Haslett et al, "Thalidomide and a Thalidomide Analogue Drug Costimulate Virus-Specific CD8+ T Cells In Vitro", The Journal of Infectious Diseases, (20030315), vol. 187, no. 6, pages 946 - 955, XP009065694
SEARCH- CORRAL L G ET AL, "IMMUNOMODULATION BY THALIDOMIDE AND THALIDOMIDE ANALOGUES", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, (19990101), vol. 58, no. SUPPL. 01, ISSN 0003-4967, pages I107 - I113, XP000861990 [Y] 1-9 * page 1110 - page 1111 *
SEARCH- LENTZSCH S ET AL, "S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20020415), vol. 62, ISSN 0008-5472, pages 2300 - 2305, XP002959459 [Y] 1-9 * page 2301, column 2, paragraph 1 *
SEARCH- CAIRA M R, "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (19980101), vol. 198, doi:10.1007/3-540-69178-2_5, ISSN 0340-1022, pages 163 - 208, XP001156954 [Y] 1-9 * Paragraph bridging pages 165-166 Chapter 3.1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents